Business · 20/10/2017Updated: 10/17/2026 · 1 min read
FDA Announces Availability of Draft Guidances for Salmeterol Xinafoate and Fluticasone Propionate
Summary
The FDA has released draft guidances for the pharmaceutical industry on generic versions of three inhalation medications, including salmeterol xinafoate and fluticasone propionate, to provide recommendations on bioequivalence studies for abbreviated new drug applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →